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West Nile virus (WNV) is a mosquito-borne flavivirus maintained in a transmission
cycle between mosquitoes and birds, but it can also infect other vertebrates, including
humans, in which it can cause neuroinvasive diseases. To date, no licensed vaccine
or therapy for human use against this pathogen is yet available. A recent approach
to search for new antiviral agent candidates is the assessment of long-used drugs
commonly administered by clinicians to treat human disorders in drug antiviral
development. In this regard, as patients with West Nile encephalitis frequently develop
symptoms and features of parkinsonism, and cellular factors altered in parkinsonism,
such as alpha-synuclein, have been shown to play a role on WNV infection, we have
assessed the effect of four drugs (L-dopa, Selegiline, Isatin, and Amantadine), that are
used as therapy for Parkinson’s disease in the inhibition of WNV multiplication. L-dopa,
Isatin, and Amantadine treatments significantly reduced the production of infectious
virus in all cell types tested, but only Amantadine reduced viral RNA levels. These results
point to antiparkinsonian drugs as possible therapeutic candidates for the development
of antiviral strategies against WNV infection.
Keywords: flavivirus, West Nile virus, neuroinvasive disease, Parkinson, antivirals, inhibition
INTRODUCTION
West Nile virus (WNV) is a mosquito-borne flavivirus of the Flaviviridae family that belongs to
the Japanese encephalitis (JEV) antigenic complex. This family includes other relevant human
pathogens as JEV, Yellow Fever (YFV), Saint Louis encephalitis (SLEV), Dengue (DENV), and
Zika (ZIKV) viruses, among others. WNV is maintained in an enzootic transmission cycle between
mosquitoes and birds, but it can also infect other vertebrates, such as horses and humans (Martin-
Acebes and Saiz, 2012). The virus is responsible for recurrent outbreaks of febrile illness and
meningoencephalitis worldwide, accounting for hundreds of human deaths every year (Martin-
Acebes and Saiz, 2012). Even though the great effort devoted in the past years to decipher the
molecular biology of WNV and its interaction with the host immune system (Brinton, 2013; Suthar
et al., 2013), no licensed vaccine or therapy for human use against this pathogen is yet available.
West Nile virus infection in humans is mainly subclinical, but approximately 20–40% of the
infected people develop symptoms of disease that range from West Nile fever (fever, headache,
lymphadenopathy, myalgia, fatigue, skin rash, diarrhea, and vomiting) to neurologic illness,
and even to death (Donadieu et al., 2013). Neuroinvasive disease includes aseptic meningitis,
encephalitis or an acute poliomyelitis-like syndrome (Davis et al., 2006; Sejvar, 2014). Patients
with West Nile encephalitis frequently develop persistent movement disorders and tremors, and
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features of parkinsonism, including hypomimia, bradykinesia,
and postural instability (Robinson et al., 2003). Likewise,
cerebellar ataxia with associated truncal instability and gait
disturbance, which induces symptoms similar to those of
parkinsonism, has also been described in patients presenting
WN encephalitis (Kanagarajan et al., 2003). Typically, these
movement disorders resolve over time; however, tremor and
parkinsonism may persist in patients recovering from WNV
severe encephalitis (Sejvar, 2014). Moreover, it has been recently
reported that parkinsonian features during WNV encephalitis
are closely related to viral-induced cell death of dopaminergic
neurons and the loss of dopamine signaling (Beatman et al.,
2015). Besides WNV, different viral infections have been
associated with parkinsonism (Jang et al., 2009), including those
caused by other flaviviruses, such as JEV (Hamaue et al., 2006) or
SLEV (Cerna et al., 1999). In fact, an early study reported that
experimentally JEV-infected Fisher rats exhibited bradykinesia
that was reversed by administration of L-dopa and of MAO
(monoamine oxidase) inhibitors, suggesting that JEV infection
induces Parkinson’s disease (PD) symptoms (Ogata et al., 1997).
All these findings suggest that flavivirus infection could share
cellular factors to those involved in parkinsonism.
Parkinson’s disease (PD) is a degenerative disorder of the
central nervous system that mainly affects the motor system
and was first described in detail in 1817 (Goetz, 2012). It is
a consequence of a loss of dopamine-generating cells in the
substantia nigra, a region of the midbrain. Early in the course
of the disease, the most obvious symptoms are movement-
related, including shaking, rigidity, slowness of movement, and
difficulty with walking. The disease can be either primary, which
is considered as idiopathic, or secondary, which can be caused, for
instance, by toxins and viral infections. Nowadays, L-dopa is the
most effective therapy available for treating the motor symptoms
of PD, however, other medications (such as MAO B inhibitors,
anticholinergics, amantadine, β-blockers, or dopamine agonist)
are used in mild symptoms to avoid L-dopa-related motor
complications (Connolly and Lang, 2014).
West Nile virus infections in humans provoke neurological
disorders associated to the development of persistent movement
disorders and tremors, similar to that observed in Parkinson’s
disease patients. During this process, CNS neurons are affected,
even leading to neuronal loss in the substantia nigra (Bosanko
et al., 2003; Schafernak and Bigio, 2006), a process also observed
in PD, in which a selective loss of dopamine-generating cells
has been reported (Samii et al., 2004; Davie, 2008). In this
regard, it has been recently described that neuronal expression of
alpha-synuclein, a protein closely linked to PD (Stefanis, 2012),
inhibits RNA viral infections in the central nervous system,
suggesting that acute onset of parkinsonian features during WNV
encephalitis could likely be due to viral-induced cell death of
dopaminergic neurons that resulted in an acute loss of dopamine
signaling (Beatman et al., 2015).
A recent approach to search for new antiviral agent candidates
is the assessment of long-used drugs commonly administered by
clinicians to treat human disorders, as part of drug repositioning
(finding of new applications to licensed drugs). Among some
of the drugs already tested as antivirals are lithium, statins, or
valproic acid (Gilbert et al., 2005; Asenjo et al., 2008; Vazquez-
Calvo et al., 2011). Likewise, the potential antiviral effect of
multiple clinical compounds have also been revealed by massive
screenings (Gastaminza et al., 2010). Since there is evidence
supporting that WNV infection shares common points with
Parkinson’s disease, we decide to study whether drugs used
for the treatment of Parkinson’s disease could provide novel
tools for antiviral intervention. In this way, we have assessed
the effect of four antiparkinsonian drugs (L-dopa, Selegiline,
Isatin, and Amantadine) in WNV multiplication in cultured cells
from different origin. L-dopa, Isatin, and Amantadine treatments
significantly reduced the production of infectious virus in all cell
types tested, but only Amantadine reduced viral RNA levels. This
results point to these drugs, especially Amantadine, as possible
therapeutic candidates for the development of antiviral strategies
against WNV infection.
MATERIALS AND METHODS
Cells, Viruses, Infections, and Virus
Titrations
Vero CCL81 (ATCC R© CCL-81TM), SH-SY5Y (ATCC R© CRL-
2266TM), and HeLa (ATCC R© CCL-2TM) cells were grown (37◦C,
5% CO2) in Eagle’s Minimum Essential Medium (EMEM; Lonza,
Verviers, Belgium, cat n◦ BE12-125F) containing 5% fetal bovine
serum (FBS; Hyclone, GE Healthcare, UK cat n◦ SV301360.03),
in Dulbecco’s modified Eagle’s medium with nutrient mixture
F-12 (DMEM/F-12(1:1); Gibco, Lifetechnologies, Carlsbad, CA,
USA, cat n◦ 11330-032) containing 10% FBS, and in DMEM
(Gibco, Lifetechnologies, cat n◦ BE12-614F) containing 10%
FBS, respectively. All media were supplemented with 2 mM
L-glutamine (Lonza, cat n◦ 17-905C) and penicillin-streptomycin
(Lonza, cat n◦ DE17-602E).
All infectious virus manipulations were performed in our
biosafety level 3 (BSL-3) facilities with a cell culture passaged
New York/1999 (NY99) WNV strain [GenBank acc.: KC407666
(Cordoba et al., 2007; Martin-Acebes and Saiz, 2011)]. Virus
infections were carried out as described (Martin-Acebes et al.,
2014). Briefly, the viral inoculum was incubated with cell
monolayers for 1 h at 37◦C, and then removed before fresh
medium containing fetal bovine serum was added. Viral titers
were determined at 16 or 24 h post-infection (p.i.) by standard
plaque assay in semisolid agarose medium. For this purpose,
10-fold serial dilutions of the supernatants in culture medium
were added to subconfluent Vero cell monolayers grown on
six-well tissue culture dishes. After 1 h of incubation at 37◦C,
viral inoculum was removed and fresh medium containing 2%
fetal bovine serum, and 1% low-melting agarose (Conda, Cat.
8092.00) was added. Plates were incubated 72 h at 37◦C and, then,
fixed with 4% formaldehyde. Lysis plaques were visualized by
staining with crystal violet. Usually, lysis plaques were scored in
sample dilutions ranging from 10−4 to 10−5 of the initial sample,
thus excluding possible effect of the remaining amounts of the
drug with viral titration experiments. A multiplicity of infection
(MOI) of 0.5 plaque forming units (PFUs)/cell were used in all
experiments, except in those involving viral entry plaque assays
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(MOI of 1 PFU/cell), and immunofluorescence assays (MOI of 5
PFU/cell).
Drug Treatments
The dopamine precursor L-dopa (cat n◦ PHR1271), the
monoaminooxidase B inhibitors (MAOI B) Selegiline [R(−)
deprenyl hydrochloride, cat n◦ M003] and Isatin (cat n◦ 114618),
and Amantadine hydrochloride (cat n◦ A1260) were purchased
from Sigma (St. Louis, MO, USA) and tested at different
concentrations. Ammonium Chloride (NH4Cl, 25 mM, cat n◦
168320) was from Merck (Darmstadt, Germany). In experiments
with NH4Cl, extracellular pH was buffered with 25 mM HEPES
at pH 7.5 (Sigma, cat n◦ H0887). Cells were infected, or mock
infected, and drugs were added to the medium at different times
prior to or after infection. Control cells were treated in parallel
with the same amount of drug vehicle (cell culture media). Cell
viability upon drug treatments was determined by measuring
the cellular ATP content with CellTiter-Glo R© luminescent cell
viability assay (Promega, Madison, WI, USA, cat n◦ G7571).
Selectivity Index Determination
Selectivity Index value (SI) was determined as the ratio of
cytotoxic concentration 50 (TC50) to inhibitory concentration
50 (IC50) for each treatment. To assess TC50, confluent SH-
SY5Y cells in 96-well cell culture microplates were treated with
a wide range of concentrations (from 0 to 300 mM), of each
compound in triplicate. The treated cells were incubated 24 h
at 37◦C, and cell viability was determined with CellTiter-Glo R©
luminescent cell viability assay according to the manufacturer
protocol. Determination of IC50 was performed by titration of the
PFU released to the supernatant of infected cultures treated with
the same concentrations of the drugs.
qRT-PCR
Viral RNA from culture supernatants was extracted using
a commercial kit (Speedtools RNA virus extraction kit,
Biotools B&M Labs S.A, Madrid, Spain cat n◦ 21142.
The amount of viral RNA was determined by real-time
fluorogenic reverse transcriptase PCR (RT-PCR) according
to a previously published protocol (Lanciotti et al., 2000).
The forward primer 5′-CAGACCACGCTACGGCG-3′, the
reverse primer 5′- CTAGGGCCGCGTGGG-3′, and the
probe 5′-FAM (6-carboxyfluorescein)- TCTGCGGAGAG
TGCAGTCTGCGAT-3′-BHQ-1 (Black Hole Quencher-1),
were used. Quantification was performed using High Scriptools-
Quantimix Easy Probes Kit (Biotools) and a Rotor-Gene RG-3000
equipment (Corbett Research) as described (Merino-Ramos et al.,
2015).
For quantification of cell-associated viral RNA, supernatants
from infected cells were removed, cell monolayers were subjected
to three freeze-thaw cycles and the RNA was extracted as
described above. Extraction of cell-associated total RNA was
performed using TRIzol reagent (Life Technologies, cat n◦
15596-026). Total RNA was then treated with RQ1 DNase
(Promega, Madison, WI, USA. cat n◦ M6101) to remove any
contaminating DNA. cDNA was synthesized with Superscript
III reverse transcriptase (Life technologies, cat n◦ 18080–18093)
with oligo dT primer, and quantified by quantitative PCR (qPCR)
with Sybr GreenER (Life technologies, cat n◦ 11762) using the
internal control ribosomal RNA 18S specific primers (Biotools,
cat n◦ 33007). Cell-associated viral RNA copies were calculated
by normalizing to the internal control. The number of viral
RNA copies is given as the number of genomic equivalents
corresponding to the number of PFU/ml by comparison with
the amount of RNA extracted from previously titrated samples
(Blazquez and Saiz, 2010; Escribano-Romero et al., 2013).
Antibodies and Staining
Mouse monoclonal antibody J2 against double-stranded RNA
(dsRNA) was from English and Scientific Consulting (Scicon,
Budapest, Hungary, cat n◦ T3605). Mouse monoclonal antibody
3.67G directed against WNV envelope protein was from
Millipore (Temecula, CA, cat n◦ MAB8150), and Topro-3 (cat n◦
T3605) and secondary antibody against mouse IgGs coupled to
Alexa Fluor-488 (cat n◦ 11001) were from Life Technologies.
Immunofluorescence
Assays were carried out as described (Blazquez et al., 2013).
Briefly, cells were grown on glass cover slips, fixed with
4% paraformaldehyde in PBS (15 min room temperature,
rt), permeabilized with BPTG (1% BSA, 0.1% TritonX-100,
1 M glycine in PBS) for 15 min, incubated with primary
antibody diluted in 1% BSA in PBS for 1 h, and then
with fluorescently conjugated secondary antibody (45 min, rt).
Finally, cells were incubated with Topro-3 (5 min, rt) and
mounted with Fluoromount-G (SouthernBiotech, cat n◦ 0100-
01). Between each step, samples were thoroughly washed with
PBS. Samples were observed using a Leica TCS SPE confocal
laser-scanning microscope, and the images were acquired using
Leica Advanced Fluorescence Software, and processed using
ImageJ (http://rsbweb.nih.gov/ij/) and Adobe Photoshop CS2.
Statistical Analyses
Data are presented as mean ± SD. One-way analysis of variance
(ANOVA) was performed using SPSS15 (SPSS Inc.). Differences
were considered statistically significant at P < 0.05.
RESULTS
Inhibition of WNV Multiplication in
Neuronal Cells by Treatment with
Antiparkinsonian Drugs
Since neural tissues constitute a major target of WNV infection
in human patients (Martin-Acebes and Saiz, 2012; Suen et al.,
2014), the human neural cell line SH-SY5Y was chosen as
a model to initially analyze the effects of antiparkinsonian
drugs treatment on WNV infection. SH-SY5Y were infected
with WNV and different concentrations of the drugs (L-dopa,
Selegiline, Isatin, or Amantadine) were added 1 h p.i. to avoid
their possible interference with virus entry. All drugs, except
Selegiline, inhibited WNV multiplication in a dose dependent
manner (Figure 1). The cytotoxicity of the treatments was
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FIGURE 1 | Inhibition of WNV in SH-SY5Y cells treated with antiparkinsonian drugs and evaluation of the cytotoxicity of the treatments on SH-SY5Y
cells by determination of cellular ATP content 24 h post-treatment. Reduction of WNV infectious particle production and ATP measurement in cells treated
with different concentrations of drugs. Cells were infected with WNV (MOI of 0.5 PFU/cell) and virus yield in culture supernatant was determined by plaque assay at
24 h p.i. Cell viability (estimated as ATP content) was determined in mock-infected cells treated with the same amount of drugs in parallel. Statistically significant
differences are indicated: ∗P < 0.05.
analyzed in parallel by determination of the cellular ATP content
(Figure 1), confirming that Isatin and Amantadine inhibited
WNV multiplication with no significant toxicity up to 1000 µM
and 750 µM, respectively. L-dopa inhibited WNV multiplication
causing no detectable cytotoxicity up to 500 µM. Compounds
that showed antiviral effects were then assessed to establish
their SIs that determines the relative effectiveness of the drug
in inhibiting viral replication compared to inducing cell death
(Table 1). Overall, these results suggest that the antiparkinsonian
L-dopa, Isatin, and Amantadine could constitute novel antiviral
agents against WNV.
Effect of Antiparkinsonian Drugs on WNV
Infection in Non-neural Cells
Since distribution of dopamine and MAO receptors are
heterogeneously expressed not only in the central nervous
TABLE 1 | Selectivity indexes (SIs) for antiparkinsonian drugs in SH-SY5Y
cells.
TC50 (mM) IC50 (mM) SI
L-dopa 70 ± 3.1 0.57 ± 0.09 122.81
Isatin 160 ± 4.6 0.78 ± 0.14 205.13
Amantadine 150 ± 1.4 0.37 ± 0.10 405.41
Selectivity index was determined by quantifying the relation between cytotoxic
concentration 50 (TC50) and inhibitory concentration 50 (IC50). TC50 is the
concentration that results in the reduction of 50% of the ATP content of the host
cells. IC50 is the concentration of drug at which virus production is inhibited by
50% determined by titration of culture supernatants standard plaque assay.
system, but also in a wide range of cells, tissues, and organs
(Missale et al., 1998; Pivonello et al., 2007), two non neural cell
lines of different origin (Vero and HeLa) were also used to assess
the antiviral effect of these drugs. These cell lines are widely used
as models for the analysis of WNV infectious lifecycle (Krishnan
et al., 2008; Gillespie et al., 2010; Martin-Acebes et al., 2014).
Considering the results obtained in SH-SY5Y cells (Figure 1),
the most effective concentration of drug that exerted minimal
effects on cell viability (500, 1000, and 750 µM for L-dopa, Isatin,
and Amantadine, respectively) was selected for the experiments
in Vero and HeLa cells. Selegiline was not included in the
analysis since this drug did not inhibit WNV infection in neural
cells (Figure 1). WNV-infected Vero cells showed a statistically
significant reduction in virus yield after treatment with L-dopa,
Isatin, or Amantadine (Figure 2A). L-dopa and Isatin inhibited
virus yield about 50%, while Amantadine did it by more than
90%. Higher inhibitory effects were even observed in HeLa cells
upon treatment with all three drugs (Figure 2B). No significant
effects on cell viability were observed at the concentrations
of drugs used in any of the cell lines tested (Figures 2A,B).
These results confirm the antiviral effect of L-dopa, Isatin, and
Amantadine in WNV susceptible non-neural cells.
Antiparkinsonian Drugs Did Not Affect
Viral Entry into the Cell
To assess the possible effect of the drugs during viral entry step,
Vero cells were infected at high (MOI of 1 PFU/cell) to ensure
that all cells were infected in a primary round of infection, thus
avoiding possible secondary infections. Treatments were added
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FIGURE 2 | Inhibition of WNV in cells treated with antiparkinsonian
drugs, evaluation of the toxicity of the treatments on cells by
determination of cellular ATP content 24 h post-treatment. Drugs
concentration were: L-dopa (500 µM), Isatin (1000 µM), and Amantadine
(750 µM). (A) Reduction of WNV infectious particle production and ATP
measurement in Vero cells treated with the drugs. Cells were infected with
WNV (MOI of 0.5 PFU/cell) and virus yield in culture supernatant was
determined by plaque assay at 24 h p.i. Cell viability (estimated as ATP
content) was determined in mock-infected cells treated with the same amount
of drugs in parallel. (B) Reduction of WNV infectious particle production and
ATP measurement in HeLa cells. Cells were infected as in (A). Statistically
significant differences are indicated: ∗P < 0.05.
to the culture medium following four different patterns: (a) 1 h
previous to the infection and then removed; (b) 1 h pre-infection
and during viral adsorption, when they were removed and
fresh medium was added; (c) 1 h pre-infection and maintained
throughout the rest of the assay (d) drugs were added only
after 1 h of infection. The amount of infectious virus released
into the culture medium was determined by plaque assay as
early as 16 h p.i. WNV-infected Vero cells showed a statistically
significant reduction in virus yield after treatment with L-dopa,
Isatin, or Amantadine when the drugs were maintained after
viral adsorption, but no significant effects were observed when
used in pre-infection or adsorption steps (Figure 3A), confirming
that none of the three compounds exerted any effect at the viral
entry step. In addition, no significant differences on the extent
of the inhibition between cells treated 1 h prior to infection and
throughout the rest of the assay and those cells treated only from
1 h p.i., suggesting that the major inhibitory effect of the drug was
produced after 1 h p.i.
To further verify these observations, the expression of WNV
envelope (E) glycoprotein was detected by inmunofluorescence
in WNV infected, or mock infected, Vero cells treated, or
not, with the drugs. All the compounds were added 1 h
prior to viral infection and kept only during the first hour
of infection. After adsorption, treatments were removed and
fresh medium was added to the cells. As a positive control
for a compound that impairs WNV entry, ammonium chloride
(25 mM NH4Cl) was added in the same conditions as the
drugs. NH4Cl is a weak base that blocks organelle acidification
and inhibits WNV infection at an entry step (Gollins and
Porterfield, 1986; Zhang et al., 2007; Martin-Acebes et al., 2013).
As expected, no expression of the WNV E glycoprotein was
detected in mock infected or in WNV infected cells treated
with NH4Cl (Figure 3B). Conversely, infected cells treated with
L-dopa, Isatin, Amantadine, or non-treated cells revealed a high
accumulation of WNV E glycoprotein. No statistically significant
differences were observed in the amount of positive cells or in the
intensity of the signal between treated and not treated cells. These
results confirmed that the antiparkinsonian drugs here evaluated
did not prevent viral entry.
Amantadine Inhibits WNV Infection at a
Replication Step
The analysis of RNA released to the supernatant of infected
cultures by quantitative RT-PCR showed a significant reduction
on the amount of viral RNA released to the culture medium only
by Amantadine (Figures 4A–C), contrary to what was observed
after treatment with L-dopa or with Isatin, where no statistically
significant inhibition of the release of genome containing units
was recorded. Since these drugs also inhibited the production
of infectious virus (Figures 1 and 2), these results suggest that
they could be inducing the release of non-infectious genome-
containing units.
To further analyze the effects of these drugs on WNV
genome replication, the amount of dsRNA intermediates, a
well characterized maker of flavivirus replication complex,
was analyzed by immunofluorescence in WNV infected Vero
cells treated or not with the drugs. As expected, no dsRNA
was detected in mock infected cells, whereas it was observed
in infected cells (Figure 5A). The intensity of the signal
in infected cells was statistically significant lower than that
displayed by non-treated control infected cells only in the case
of Amantadine (Figure 5B). Furthermore, quantification of cell-
associated viral RNA by qRT-PCR confirmed the results obtained
by immunofluorescence. Treatment with Amantadine showed a
statistically significant reduction in the amount of cell-associated
RNA relative to control samples and, to a lesser degree, this
reduction was also observed with L-dopa or Isatin treatments,
suggesting that treatment with either Amantadine, L-dopa, or
Isatin, induce an impairment in WNV viral replication in cell
culture (Figures 5C–E).
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FIGURE 3 | (A) Reduction of WNV infectious particle production in Vero cells treated with the drugs 1 h prior to infection and during the adsorption. Drugs
concentration were: L-dopa (500 µM), Isatin (1000 µM), and Amantadine (750 µM). Supernatants were collected at 16 h p.i. (B) Visualization of the expression of
WNV E glycoprotein in cells infected with WNV (MOI of 5 PFU/cell) and treated with drugs 1 h prior to infection and during the adsorption period. Drugs
concentration were as in (A). Vero cells were fixed at 16 h p.i. and processed for immunofluorescence using a monoclonal antibody against WNV-E protein and a
secondary antibody coupled to Alexa Fluor 488. Nuclei were stained with ToPro-3. Mock-infected cells processed in parallel were included as control. WNV infected
cells treated with NH4Cl 25 mM were also used as a positive control of a drug that inhibits viral entry. Statistically significant differences are indicated: ∗P < 0.05.
DISCUSSION
West Nile virus infections in humans have been reported
to provoke meningitis and encephalitis associated to the
development of persistent movement disorders and tremors.
During this process, CNS neurons are affected, even leading
to neuronal loss, gliosis, and neurofibrillary tangle formation
in the substantia nigra (Bosanko et al., 2003; Schafernak and
Bigio, 2006). In this regard, it is known that the selective
loss of dopamine-generating cells in the substantia nigra is
responsible for the development of Parkinson’s disease (Samii
et al., 2004; Davie, 2008). Even more, it has been recently reported
that neuronal expression of alpha-synuclein, a protein closely
linked to PD (Stefanis, 2012), inhibited RNA viral infections
in the central nervous system, suggesting that acute onset of
parkinsonian features during WNV encephalitis are likely due
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FIGURE 4 | Quantification of viral RNA in the culture supernatant of
cells infected with WNV (MOI of 0.5 PFU/cell) by quantitative RT-PCR
(24 h p.i.). (A) Quantification in Vero (A), HeLa (B), and SH-SY5Y cells (C).
Drugs concentration were: L-dopa (500 µM), Isatin (1000 µM), and
Amantadine (750 µM). Statistically significant differences are indicated:
∗P < 0.05.
to viral-induced cell death of dopaminergic neurons resulting in
acute loss of dopamine signaling (Beatman et al., 2015).
Nowadays, the main used therapies for treating motor
symptoms associated to parkinsonism are L-dopa (250 mg/day),
dopamine agonists, and MAO-B inhibitors (selegiline
10 mg/day). Thus, following the recently trend to test
drugs commonly administered to treat human disorders as
innovative antiviral therapies, in this study, the effect on WNV
multiplication of four different antiparkinsonian drugs has
been addressed. A significant inhibition of WNV multiplication
after treatment with L-dopa was observed in all the cell
lines tested, independently of their neuronal origin or not.
This probably reflects the fact that dopamine receptors are
heterogeneously expressed in a wide range of cells, tissues and
organs (Pivonello et al., 2007). Similar results were obtained with
the MAO-B inhibitor (MAOI B) Isatin, which is not currently
used in clinical therapy. In contrast, no positive results were
recorded, independently of concentration or cell line used, when
Selegiline, another MAOI B widely used in PD, was tested.
These discrepancies, even though both drugs inhibit the same
enzyme in the degradation of dopamine, could be due to their
different mechanisms of action, being Isatin an endogenous
inhibitor of the MAO B, while Selegiline belongs to the group of
irreversible inhibitors of the enzyme. In fact, previous data have
also reported a lower effect on bradykinesia and dopamine levels
when Selegiline was administered to JEV-infected rats (Hamaue
et al., 2004).
Among the antiparkinsonian drugs assayed, Amantadine
showed the highest inhibitory effect in WNV infection, over
90% inhibition in virus yield in all cell lines tested. Amantadine
began to be used in treating Parkinson’s disease in the 1960’s
at dosages of 200 mg/day (Schwab et al., 1969) and, although
its mechanism of action still remains unclear, it has been
postulated to inhibit NMDA (N-methyl-D-Aspartate) receptors
(Blanpied et al., 2005), and to release dopamine from the nerve
endings of the brain cells together with the stimulation of a
norepinephrine response DrugBank (n.d.). About the same time,
Amantadine was recognized as an antiviral agent (Davies et al.,
1964) that, since then, it has been used, among others, for
influenza viral infections (Beigel and Bray, 2008; Razonable, 2011;
Benschop et al., 2015). Our results indicate that Amantadine
statistically significantly inhibited WNV replication, measured
by either the release of viral RNA to the culture medium, or
the quantification of cell-associated RNA, as well as the amount
of dsRNA intermediates. The percentage of genome-containing
units obtained after Amantadine treatment ranged, depending
on the cell line, from 8 to 18% compared to untreated infected
cells. The reduction in the amount of cell-associated viral RNA
compared to untreated samples in any cell line tested and the
lower amount of dsRNA intermediates observed in infected cells
treated with this drug suggest an impairment of the proper
development of WNV replication complexes. Differences in the
WNV inhibition capability showed between L-dopa or Isatin
treated cells when compared with that of Amantadine point that
this drug is not only acting at dopamine receptor level, as different
antiviral mechanisms of the drug have been proposed DrugBank
(n.d.). For instance, Amantadine can inhibit virus multiplication
Frontiers in Microbiology | www.frontiersin.org 7 March 2016 | Volume 7 | Article 296
fmicb-07-00296 March 3, 2016 Time: 19:45 # 8
Blázquez et al. Anti-Parkinsonian Drugs and WNV
FIGURE 5 | (A) Visualization of intracellular dsRNA accumulation in cells infected with WNV (MOI = 5 PFU/cell) and treated with drugs at 24 h p.i. Drugs
concentration were: L-dopa (500 µM), Isatin (1000 µM), and Amantadine (750 µM). Vero cells were fixed and processed for immunofluorescence using monoclonal
antibody against dsRNA J2 and a secondary antibody coupled to Alexa Fluor 488. Nuclei were stained with ToPro-3. Mock-infected cells processed in parallel are
also included as a control. The panels in the last file display dsRNA staining with false coloring from dark purple to bright yellow by use of the fire lookup table (LUT)
scheme to highlight differences in the intensities of the signals. Bars, 10 µm. (B) Quantification of the fluorescence intensity of dsRNA in cells infected and treated
with drugs as shown in (A). (C–E) Quantification of RNA genomic equivalents in cell-associated viral RNA in cell cultures infected with WNV (MOI of 0.5 PFU/cell) and
treated with antiparkinsonian drugs determined by quantitative RT-PCR at 24 h p.i. Quantification of cell-associated WNV RNA in (C) Vero, (D) HeLa, and
(E) SH-SY5Y cells. Genomic equivalents were normalized using cellular 18S RNA as an internal control. Statistically significant differences are indicated: ∗P < 0.05.
at the maturation step by blocking viroporins participating in the
adjustment of the pH of the environment in transport vesicle.
However, to our knowledge, Hepatitis C virus (HCV) is the only
member of the Flaviviridae family which contains viroporins
in its genome (Madan and Bartenschlager, 2015). In fact, HCV
viroporin protein p7-like is not present in WNV, and no other
viroporins have currently been described for any members of the
Flavivirus genus. Therefore, vioporins blocking does not seem to
be involved in Amantadine inhibition of WNV multiplication.
On the other hand, the interference of Amantadine with virus
uncoating has been previously described for influenza (Stanicˇova
et al., 2001). However, in our study the lack of effect of the
tested drugs at the viral entry step has been demonstrated.
No differences were observed by immunofluorescence in the
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expression of the viral E glycoprotein between treated and not
treated cells when drugs were administered 1 h prior to infection,
kept during viral adsorption, and then removed. Even more, our
results indicated that virus yield was significantly decreased in
infected Vero cells only when drugs were kept after infection,
while it was not affected when the drugs were removed after viral
adsorption.
The results presented in this study point to a possible
therapeutic antiviral potential of antiparkinsonian drugs in
the inhibition of neurotropic viruses such as WNV, which
should be further confirmed in vivo. It has been thoroughly
demonstrated that efficacy of antiviral drugs toward the
cerebral viral load is often limited by the ability to cross
the blood–brain barrier (BBB) (Groothuis and Levy, 1997;
Strazielle and Ghersi-Egea, 2005). In this sense, the use of
drugs widely applied in the treatment of neurological diseases
overcomes the difficulties to reach the target, being a good
starting point for antiviral development against WNV and
other related neurovirulent flaviviral infections. In fact, it has
to be considered that antiparkinsonian drugs can inhibit the
parkinsonian symptoms of related flaviviruses in animal models
(Hamaue et al., 2004). However, animal model experiments
testing the dosages used in the patients treated with the
antiparkinsonian drugs currently used in clinics that successfully
inhibited WNV multiplication in cultured cells (L-dopa and
amantadine), should be performed to evaluate if the in vitro
effect observed against WNV could correlate with an in vivo
effect.
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